Literature DB >> 17623075

Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.

Changbao Liu1, Nicole D Day, Patrick J Branigan, Lester L Gutshall, Robert T Sarisky, Alfred M Del Vecchio.   

Abstract

To elucidate the relationship between resistance to HRSV neutralizing antibodies directed against the F protein and the fusion activity of the F protein, a recombinant approach was used to generate a panel of mutations in the major antigenic sites of the F protein. These mutant proteins were assayed for neutralizing mAb binding (ch101F, palivizumab, and MAb19), level of expression, post-translational processing, cell surface expression, and fusion activity. Functional analysis of the fusion activity of the panel of mutations revealed that the fusion activity of the F protein is tolerant to multiple changes in the site II and IV/V/VI region in contrast with the somewhat limited spectrum of changes in the F protein identified from the isolation of HRSV neutralizing antibody virus escape mutants. This finding suggests that aspects other than fusion activity may limit the spectrum of changes tolerated within the F protein that are selected for by neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17623075      PMCID: PMC1947961          DOI: 10.1186/1743-422X-4-71

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


  29 in total

1.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.

Authors:  Sheng-Jiun Wu; Albert Schmidt; Eric J Beil; Nicole D Day; Patrick J Branigan; Changbao Liu; Lester L Gutshall; Concepción Palomo; Julie Furze; Geraldine Taylor; José A Melero; Ping Tsui; Alfred M Del Vecchio; Marian Kruszynski
Journal:  J Gen Virol       Date:  2007-10       Impact factor: 3.891

3.  Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins.

Authors:  B García-Barreno; C Palomo; C Peñas; T Delgado; P Perez-Breña; J A Melero
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization.

Authors:  M Trudel; F Nadon; C Séguin; P Payment; P J Talbot
Journal:  Can J Microbiol       Date:  1987-10       Impact factor: 2.419

Review 5.  Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus.

Authors:  Lone Graff Stensballe; Jayanth K Devasundaram; Eric A Simoes
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

6.  Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

Authors:  Sunee Techaarpornkul; Peter L Collins; Mark E Peeples
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

7.  Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.

Authors:  Xiaodong Zhao; Fu-Ping Chen; Wayne M Sullender
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

8.  Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Authors:  Timothy F Feltes; Allison K Cabalka; H Cody Meissner; Franco M Piazza; David A Carlin; Franklin H Top; Edward M Connor; Henry M Sondheimer
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

9.  Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.

Authors:  L J Anderson; P Bingham; J C Hierholzer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

Authors:  John P DeVincenzo; Caroline B Hall; David W Kimberlin; Pablo J Sánchez; William J Rodriguez; Barbara A Jantausch; Lawrence Corey; Jeffrey S Kahn; Janet A Englund; JoAnn A Suzich; Frances J Palmer-Hill; Luis Branco; Syd Johnson; Nita K Patel; Franco M Piazza
Journal:  J Infect Dis       Date:  2004-07-27       Impact factor: 5.226

View more
  4 in total

1.  Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.

Authors:  Jason S McLellan; Man Chen; Jung-San Chang; Yongping Yang; Albert Kim; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

2.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.

Authors:  Kurt A Swanson; Ethan C Settembre; Christine A Shaw; Antu K Dey; Rino Rappuoli; Christian W Mandl; Philip R Dormitzer; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-17       Impact factor: 11.205

3.  Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.

Authors:  John T Bates; Christopher J Keefer; James C Slaughter; Daniel W Kulp; William R Schief; James E Crowe
Journal:  Virology       Date:  2014-03-03       Impact factor: 3.616

4.  Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.

Authors:  Jarrod J Mousa; Elad Binshtein; Stacey Human; Rachel H Fong; Gabriela Alvarado; Benjamin J Doranz; Martin L Moore; Melanie D Ohi; James E Crowe
Journal:  PLoS Pathog       Date:  2018-02-22       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.